Table 1: Kinase Activity and Ligand Binding Capability ... Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nature Reviews Cancer 4, 361–370 (2004) doi:10. ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

The ERBB receptors are a group of receptor tyrosine kinases (RTKs) involved in key cellular functions including cell growth and survival. What are the activation mechanisms particular to ERBBs?

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

At the recent AAAAI/WAO meeting, Blueprint Medicines Corp. presented the in vitro and in vivo characterization of BLU-808, a selective inhibitor of wild-type KIT, a transmembrane receptor tyrosine ...

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...

Henan Medinno Pharmaceutical Technology Co. Ltd. has identified deuterated non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1, JAK2 and JAK3 inhibitors reported to be useful ...

The Falke group is currently investigating the molecular mechanisms of on-off switching of components within the chemosensory array, especially the mechanisms by which transmembrane receptors bind ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...